	US 12,240,906 B2
	Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Zhuozhi Wang, Shanghai (CN); Jing Li, Lexington, MA (US); Gennady Gololobov, Gaithersburg, MD (US); and Jianqing Xu, Shanghai (CN)
Assigned to WUXI Biologics (Shanghai) Co., Ltd., Shanghai (CN)
Filed by WUXI Biologics (Shanghai) Co., Ltd., Shanghai (CN)
Filed on Mar. 21, 2023, as Appl. No. 18/187,475.
Application 18/187,475 is a continuation of application No. 16/614,777, granted, now 11,643,463, previously published as PCT/CN2017/085134, filed on May 19, 2017.
Prior Publication US 2023/0382994 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2818 (2013.01) [C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

6 Claims

1. An immunoglobulin comprising an anti-CTLA4 antibody that specifically binds to CTLA4 on the same epitope as an antibody comprising:

a) a variable region of a heavy chain having an amino acid sequence that is identical to SEQ ID NO: 7; and

b) a variable region of a light chain having an amino acid sequence that is identical to SEQ ID NO: 14.